0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 5.2100
  • Day Range
  • 52 Week Range
    Low 4.0700
    High 12.4500
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 5.21
09:36 ET9435.25
09:38 ET7005.25
09:52 ET1005.23
09:54 ET5005.22
10:06 ET20095.24
10:08 ET18005.25
10:10 ET1005.25
10:17 ET5005.2
10:19 ET2005.2004
10:30 ET8455.14
10:39 ET14915.17
10:46 ET4005.12
10:55 ET5735.18
11:09 ET11005.2
11:11 ET11005.2
11:24 ET1005.25
11:26 ET5005.27
11:27 ET23005.3
11:38 ET6005.47
11:54 ET1005.43
12:07 ET1005.3027
12:12 ET1005.42
12:38 ET2005.38
12:45 ET1005.32
12:52 ET2005.36
01:06 ET1005.36
01:33 ET1005.35
01:50 ET1005.34
02:13 ET3005.34
02:29 ET9005.3
02:36 ET1005.34
02:42 ET1005.27
02:51 ET1005.34
02:58 ET1005.34
03:16 ET127955.32
03:18 ET5005.32
03:20 ET5005.32
03:21 ET6005.32
03:25 ET1005.34
03:32 ET2005.34
03:36 ET5015.29
03:41 ET5005.32
03:45 ET1005.32
03:52 ET1005.32
03:54 ET2995.29
03:56 ET3005.35
03:57 ET2005.35
03:59 ET30015.35
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMOR
MorphoSys AG
United StatesAMYT
Amryt Pharma PLC
United StatesALEC
Alector Inc
United StatesMCRB
Seres Therapeutics Inc
United StatesANIK
Anika Therapeutics Inc
United StatesSLGC
Somalogic Inc
As of 2022-10-04

Company Information

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Contact Information

Semmelweisstr. 7PLANEGG, Germany 82152


Independent Chairman of the Supervisory Board
Marc Cluzel
Chairman of the Management Board, Chief Executive Officer
Jean-Paul Kress
Independent Deputy Chairman Member of the Supervisory Board
George Golumbeski
Chief Financial Officer, Member of the Management Board
Sung Lee
Chief Research and Development Officer, Member of the Management Board
Malte Peters

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.